Gregor Diagnostics

Gregor Diagnostics develops a molecular screening test that determines prostate cancer aggressiveness.

: 8
: Private company
: 2016
: Dallas, TX, USUnited States

Library

Coverage

5 items

Semen RNA-Based Biomarkers for Prostate Cancer Detection and Risk Stratification: A Prospective Multicenter Validation Studyauajournals.org/doi/abs/10.1097/JU.0000000000005123
Researchers validate semen RNA biomarkers to detect prostate cancer and classify its severity across multiple centers. The study evaluates diagnostic accuracy in distinguishing cancer grade groups using a prospective design. Findings aim to support non-invasive risk stratification for patients undergoing screening or monitoring.
May 2024Journal of UrologyNews article
Startup Gregor Diagnostics advances novel diagnostic technologynews.wisc.edu/gregor-diagnostics-advances-novel-prostate-cancer-diagnostic-technology/
Gregor Diagnostics develops a new diagnostic tool for prostate cancer using technology originally from the University of Wisconsin (UW). The startup exemplifies how academic research translates into commercial solutions addressing critical healthcare needs. The company aims to improve early detection methods for prostate cancer, potentially benefiting patients and creating employment opportunities.
Feb 2021NewsNews article
Gregor Diagnostics Raises $0.9 Million Seed Funding in Julysiliconprairienews.com/2018/09/gregor-diagnostics-raises-0-9-million-seed-funding-in-july/
Gregor Diagnostics secures $900,000 in seed funding led by First Round Capital and Green Park & Golf Ventures. The Madison-based startup focuses on diagnostic solutions, though specific product details are not disclosed in the announcement. The funding round highlights early-stage investor interest in health-tech innovation.
Sep 2018Silicon Prairie NewsNews article
Gregor Diagnostics licenses prostate cancer biomarker technologies from WARFwarf.org/news/gregor-diagnostics-licenses-prostate-cancer-biomarker-technologies-from-warf/
Gregor Diagnostics secures an exclusive license for prostate cancer biomarker technologies from WARF. The molecular diagnostics company is developing a novel screening test for early detection of prostate cancer. The agreement grants Gregor access to proprietary biomarker research to advance its diagnostic platform.
Sep 2017WARFNews article